Megan CassidyMegan Cassidy completed her BSc in Biology at the University of Bath. During her degree she spent a placement year at Astex Pharmaceuticals in Cambridge investigating the effect of activating MEK mutations on resistance to ERK pathway inhibitors.
This prompted her interest in signalling pathways and she joined Simon’s lab at the Babraham Institiute in 2017 as a Research Assistant working on a collaboration with Phoremost to develop a novel tools to identify ERK pathway inhibitors. Having found the Cook lab to her liking she decided to stay and Simon found no particular reason to object so she started her PhD in Oct 2018.
Outside of work Megan enjoys various sports (including cycling and swimming), playing her instruments (oboe and guitar, not at the same time) and cuddling her cat (yes, really!)
Myers SM, Miller DC, Molyneux L
European journal of medicinal chemistry
178 1768-3254:530-543 (2019)
MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAF amplification whereas KRAS amplification promotes EMT-chemoresistance.
Sale MJ, Balmanno K, Saxena J
10 2041-1723:2030 (2019)
Over-expressed, N-terminally truncated BRAF is detected in the nucleus of cells with nuclear phosphorylated MEK and ERK.
Hey F, Andreadi C, Noble C
4 2405-8440:e01065 (2018)
Targeting IKKβ in Cancer: Challenges and Opportunities for the Therapeutic Utilisation of IKKβ Inhibitors.
Prescott JA, Cook SJ
7 2073-4409: (2018)
Kidger AM, Sipthorp J, Cook SJ
Pharmacology & therapeutics
Kidger AM, Cook SJ
The FEBS journal
285 1742-4658:42-45 (2018)
Calcium phosphate particles stimulate interleukin-1β release from human vascular smooth muscle cells: A role for spleen tyrosine kinase and exosome release.
Dautova Y, Kapustin AN, Pappert K
Journal of molecular and cellular cardiology
ERK1/2 signalling protects against apoptosis following endoplasmic reticulum stress but cannot provide long-term protection against BAX/BAK-independent cell death.
Darling NJ, Balmanno K, Cook SJ
12 1932-6203:e0184907 (2017)
Cook SJ, Stuart K, Gilley R
The FEBS journal
Sipthorp J, Lebraud H, Gilley R
Galloway A, Saveliev A, Łukasiak S
Science (New York, N.Y.)
352 1095-9203:453-9 (2016)
Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation.
Lochhead PA, Clark J, Wang LZ
Cell cycle (Georgetown, Tex.)
15 1551-4005:506-18 (2016)